Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 55 Prostatic Neoplasms 46 Glioblastoma 28 Brain Neoplasms 25 Neoplasms 23 Glioma 21 Carcinoma, Non-Small-Cell Lung 19 Lung Neoplasms 18 Carcinoma, Hepatocellular 14 Gliosarcoma 13 Colorectal Neoplasms 12 Uterine Cervical Neoplasms 11 Neoplasm Metastasis 11 Rectal Neoplasms 10 Lymphoma, Non-Hodgkin 10 Oligodendroglioma 9 Melanoma 9 Central Nervous System Neoplasms 9 Astrocytoma 9 Lymphoma 8 Head and Neck Neoplasms 8 Esophageal Neoplasms 8 Colonic Neoplasms 8 Ependymoma 7 Squamous Cell Carcinoma of Head and Neck 6 Pancreatic Neoplasms 6 Lymphoma, Large B-Cell, Diffuse 6 Carcinoma, Renal Cell 6 Breast Neoplasms, Male 6 Ovarian Neoplasms 5

Interventions

pralsetinib 1 motexafin gadolinium 1 exemestane 1 entinostat 1 durvalumab 1 camrelizumab 1 belinostat 1 belagenpumatucel L 1 Tyrosine Kinase Inhibitors 1 Radiosurgery 1 Pemetrexed 1 Mediastinoscopy 1 Magnetic Resonance Spectroscopy 1 Fluticasone 1 Fluorouracil 1 Erlotinib Hydrochloride 1 Dasatinib 1 Carboplatin 1 Bronchoscopy 1 Afatinib 1 Acetylcysteine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma, Bronchogenic × Magnetic Resonance Spectroscopy × Clear all

NCT00652769 2017-11-01

BOOST

University College London Hospitals

Phase 3 Completed

Carcinoma, Bronchogenic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡